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Conclusion: It can be concluded that the adjuvant property
f propolis ethanol extract may be useful for the stimulation of
umoral immuneresponses invaccinedesign for infectiousdisease.
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asopharyngeal colonization of Streptococcus pneumoniae in
lderly people, in Jakarta, Indonesia
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Background: Streptococcus pneumoniae (S. pneumoniae) is a
eading cause of bacterial pneumonia, meningitis, and sepsis
orldwide. Incidence of invasive pneumococcal disease varies sub-
tantially by age, genetic background, socioeconomic and immune
tatus, and geographical location. Currently, few data exist on
neumococcal colonization in Indonesia. We only identiﬁed one
neumococcal colonization study in healthy children in Indonesia
Lombok Island) in 2001. Moreover, no data are yet available on
neumococcal colonization in elderly people in Indonesia.
Methods: A cross-sectional study was performed to investigate
he nasopharyngeal colonization of S. pneumonia in elderly people
uring routine clinic visits in Jakarta, Indonesia. 155 nasopharyn-
eal swabs were collected in STGG medium and cultured on blood
gar plateswith gentamicin and thus screened for alpha-hemolysis
nd optochin sensitivity. Molecular identiﬁcation of S. pneumo-
iae was also done by detection of psaA and lytA genes and the
NA analysis of .RecA and 16 s rRNA genes. Capsular serotyping was
etermined by sequentialmultiplex PCR and antibiotic susceptibil-
ty test was performed by etest method.
Results: We found ten a-haemolytic gram-positive isolates,
owever only four isolates were optochin susceptible and posi-
ive result for PsaA and LytA genes detection with the colonization
revalence is 2.6%. The three serotypes found were 3, 6A/B, 15B/C
nd one non-typeable. All pneumococcal isolate are susceptible to
enicillin and vancomycin.
Conclusion: The prevalence of nasopharyngeal colonization
f S. pneumoniae is low in elderly people in Jakarta, Indonesia.
his research will be important for pneumococcal surveillance in
ndonesia and application of pneumococcal vaccine in the future.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1011fectious Diseases 16S (2012) e158–e316 e313
Type: Poster Presentation
Final Abstract Number: 48.030
Session: Vaccines & Vaccine Development
Date: Friday, June 15, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
Immunogenicity and safety of a primary series of a new fully
liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (HexaximTM)
co-administeredwithPrevenarTM andRotarixTM inhealthy chil-
dren in Latin America
P. Lopez1, A. Arguedas Mohs2, M.-C. Miranda3, B. Zambrano4, E.
Santos Lima5,∗
1 Centro de Estudios en Infectologia Pediatrica, Cali, Colombia
2 Instituto de Atención Pediátrica, San José de Costa Rica, Costa Rica
3 Sanoﬁ Pasteur, Bogota, Colombia
4 Sanoﬁ Pasteur, Montevideo, Uruguay
5 Sanoﬁ Pasteur, Marcy l’Etoile, France
Background: Lot-to-lot consistency study assessing primary
series vaccination with a new, fully liquid, DTaP–IPV–Hep B–PRP-T
vaccine (HexaximTM - an AcXim family vaccine), incorporating the
newHansenulapolymorpha–derivedHepBantigen (SanoﬁPasteur),
co-administered with PrevenarTM and RotarixTM.
Methods: Phase III, randomized, observer-blind, two-centre
study. Subjects received Hexaxim (Group 1: N=1002 [3 lots-
pooled]) or Infanrix hexaTM (Group 2: N=338) at 2,4,6 months-
of-age, co-administered with Prevenar (PCV7: 2, 4, 6 months) and
Rotarix (2, 4months).HepBwasgivenat birth. Antibody concentra-
tions or titers were measured pre-(Hep B, D, PT, FHA) and 1 month
post-(all valences) primary series for Hexaxim and Infanrix hexa.
Equivalence of Hexaxim lots was tested. Non–inferiority analyses
were performed for Group 1 versus Group 2 for seroprotection (SP:
anti- Hep B, PRP, D, T, and polio 1/2/3) and vaccine response (VR:
anti-PTandFHA) rates.Anti-PCV7 (7months) andanti-rotavirus IgA
(5months)werealsoassessed. Safetyafter eachdosewascompared
descriptively.
Results: Equivalence was demonstrated for the Hexaxim lots,
so Group 1 data were pooled for non-inferiority testing (per pro-
tocol analysis set). For all SP and VR rates, Group 1-minus-Group 2
non-inferioritywasdemonstrated (lower95%CI bound for eachdif-
ferencewas greater than the pre-speciﬁed non–inferioritymargin).
Anti-Hep B GMCs were similar in Groups 1 and 2 (3013 and 2766
mIU/mL); anti-PRPwas higher in Group 1 (3.56 versus 2.24g/mL).
There were no clinically relevant differences in the immune
responses to Prevenar or Rotarix following co-administration with
Hexaximor Infanrix hexa. Reactogenicitywas similar in each group
and no vaccine–related SAEs were reported.
Table 1: SP or VR (95% CI)
Group 1 Group 2
Anti-Hep B ≥10 mlU/mL 99.7 (99.1;99.9) 100(98.8;100)
Anti-PRP ≥ 0 15 ug/mL 94.6 (93.0;96.0) 95.9(93.1;97.8)
Anti-Diphtheria ≥ 0.01 IU/mL 100(99.6;100) 100(98.8;100)
Anti-Tetanus ≥ 0.01 IU/mL 100 (99.6;100) 100(98.8;100)
Anti-Polio 1 ≥8 (1/dil) 100 (99.6;100) 100(98.8;100)
Anti-Polio 2 ≥8 (1/dil) 100 (99.6;100) 100(98.8;100)
Anti-Polio 3 ≥8 (1/dil) 100(99.6;100) 99.7(98.2;100)
Anti-PT (EU/mL) 97.5 (96.3;98.4) 98.4 (96.3;99.5)
Anti-FHA (EU/mL) 99.8(99.2;100) 99.4 (97.7;99.9)
Conclusion: The new DTaP-IPV-Hep B-PRP-T vaccine is
immunogenic and safe following co-administration with Prevenar
and Rotarix, and similar to the licensed comparator.
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